Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus

WHO welcomes news of Merck’s antiviral Covid pill, awaits data ahead of approval

Chidinma AnyalewechibyChidinma Anyalewechi
1 year ago
in Coronavirus
WHO welcomes news of Merck’s antiviral Covid pill, awaits data ahead of approval
Share on FacebookShare on TwitterShare on Linkedin

The World Health Organisation has welcomed Merck’s announcement of its Covid-19 antiviral pill. On Tuesday, the health organization said that Merck’s announcement of the effectiveness of its experimental antiviral pill against the most severe outcomes of Covid-19 is certainly good news.

Merck, the U.S. drugmaker announced on Friday that the antiviral pill named “Molnupiravir” has been proven to reduce the risk of hospitalization or death by around 50% for adults with mild to moderate cases of Covid.

In the phase three trial, it was discovered that the pill works by inhibiting the replication of the virus inside the body.

Why this matters

The international agency has said it awaits clinical trial data on the drug. The WHO’s technical lead for Covid, Maria Van Kerkhove said, “We’re looking forward to receiving the data from them. I think everybody wants earlier treatment so that we prevent people from actually, you know, getting to that severe state and actually dying from the disease.”

Once the clinical trial data is available, the consideration to approved treatment will commence by the FDA. If the antiviral pill is given the green light and is approved by the Food and Drug Administration, it would potentially be the first pill to treat Covid.

A potentially game-changing advancement in the fight against the virus, which is killing an average of more than 1,700 Americans per day.

According to health experts, while vaccinations remain the best form of protection against the virus, a pill like Merck’s could keep the disease from progressing in those who do get infected and prevent trips to the hospital.

What they are saying

Dr. Mike Ryan, Executive Director of WHO’s Health Emergencies Program said that pills like Merck’s are considered a sort of “holy grail” for treatments, stating that the agency is still awaiting the raw clinical trial data on the drug.

Meanwhile, other drugmakers are also working on antiviral pills. In April, the CEO of Pfizer, Albert Bourla, said that the company is working on developing a pill like Merck’s, stating that it could be available by the end of this year.

The CEO also said that world leaders and public health officials should consider the cost of the drug on patients. He said, “The cost of treating millions of people early could have a significant cost, and maybe worth that investment but we have to look at how that’s going to work”.

Related

Tags: Dr. Mike RyanWHOWorld Health Organisation

Leave a Reply Cancel reply

HFM
Mega Millions
Mega Millions
Standard
Patricia





NM newsletters

Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

Recent News

  • 11 things to expect from the Crypto market in 2023
  • FUGAZ investors gain N24.3 billion during the week
  • Amid a bearish market, Voltron Capital sees opportunities investing more in African startups

Follow us on social media:

Recent News

Why it's a bad idea to bet against the Crypto market right now

11 things to expect from the Crypto market in 2023

January 29, 2023
FUGAZ investors gain N24.3 billion during the week

FUGAZ investors gain N24.3 billion during the week

January 29, 2023
  • Home
  • Exclusives
  • Markets
  • Industries
  • Economy
  • Business News
  • Financial Literacy
  • Lifestyle
  • Opinions

© 2023 Nairametrics

No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Nairalytics
    • Macro-Economic News
    • Research Analysis
    • Budget
    • Public Debt
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds

© 2023 Nairametrics